| Active substance | Ciprofloxacin (C17H18FN3O3) |
| US Brand | Ciloxan, Cipro, Neofloxin |
| IN Brand | Ciplox |
| Manufacturing by | Cipla, India |
| Strength | 250mg, 500mg |
| Form release | Blister 10 pills |
| Estimated shipping time | 7 – 18 days (Depending from the Country) |
| Availability, Prices & Order | through request form |
Ciprofloxacin is an antibiotic used to treat a number of bacterial infections. This includes bone and joint infections, intra abdominal infections, certain type of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. For some infections it is used in addition to other antibiotics. It can be taken by mouth or used intravenously.
Ciprofloxacin is used to treat a wide variety of infections, including infections of bones and joints, endocarditis, gastroenteritis, malignant otitis externa, respiratory tract infections, cellulitis, urinary tract infections, prostatitis, anthrax, and chancroid.
Ciprofloxacin only treats bacterial infections; it does not treat viral infections such as the common cold. For certain uses including acute sinusitis, lower respiratory tract infections and uncomplicated gonorrhea, ciprofloxacin is not considered a first-line agent.
Ciprofloxacin occupies an important role in treatment guidelines issued by major medical societies for the treatment of serious infections, especially those likely to be caused by Gram-negative bacteria, including Pseudomonas aeruginosa. For example, ciprofloxacin in combination with metronidazole is one of several first-line antibiotic regimens recommended by the Infectious Diseases Society of America for the treatment of community-acquired abdominal infections in adults. It also features prominently in treatment guidelines for acute pyelonephritis, complicated or hospital-acquired urinary tract infection, acute or chronic prostatitis, certain types of endocarditis, certain skin infections, and prosthetic joint infections.
Usual Adult Dose for Inhalation Bacillus anthracis
IV: 400 mg IV every 12 hours
Oral: 500 mg orally every 12 hours
Duration of therapy: 60 days
Comments:
-Therapy should be started as soon as possible after suspected/confirmed exposure.
-Indication based on efficacy studies in animals.
Use: For treatment of inhalational anthrax (postexposure) to reduce incidence/progression of disease after exposure to aerosolized Bacillus anthracis
Rates of side effects appear to be higher than with some groups of antibiotics such as cephalosporins but lower than with others such as clindamycin. Compared to other antibiotics some studies find a higher rate of side effects while others find no difference.
